Zerbor/iStock via Getty Images Shares of Allurion ( NYSE: ALUR ) shot up nearly 160% in afternoon trading Thursday after the company announced positive data for its Allurion Program for weight loss, which features a swallowable gastric balloon and monitoring apps. The company said a newly published study showed an average lean mass gain of 5.6% in patients on the program, with an average weight loss of 14% at four months.
It noted that weight loss programs with GLP-1 drugs often result in the loss of lean muscle mass along with body fat, according to a statement . The study was published in a special issue of Clinical Nutrition in Metabolic Disorders . More on Allurion Technologies Allurion Technologies Inc.
(ALUR) Q1 2024 Earnings Call Transcript Allurion expects Q1 revenue in the range of $9.2M to $9.3M Allurion stock soars 85% on weight-loss product launch Seeking Alpha’s Quant Rating on Allurion Technologies Historical earnings data for Allurion Technologies.
